Physician profile
Daniel Castro
NPI 1316320179
$1,853.61
in general payments reported to CMS, 2019-2025
23 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $108 · 2021: $474 · 2022: $634 · 2023: $58.95 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $490.47 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $274.72 | 2019-2025 | |
| Abbvie INC. | $194.73 | 2022-2023 | Venclexta |
| Genzyme Corporation | $124.82 | 2022 | |
| Amgen INC. | $85.71 | 2021 | |
| Dendreon Pharmaceuticals LLC | $73.95 | 2025 | Provenge |
| Caris Mpi, INC. | $69.28 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $64.77 | 2022-2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $56.26 | 2025 | Rybrevant |
| Genmab U.S., INC. | $55.59 | 2022 | |
| Celgene Corporation | $53.06 | 2022-2025 | Reblozyl |
| Eisai INC. | $43.49 | 2022 | |
| Astellas Pharma US INC | $36.85 | 2022 | |
| Glaxosmithkline, LLC. | $33.28 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.55 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.83 | 2025 | |
| Geron Corporation | $25.01 | 2025 | Rytelo |
| Lilly USA, LLC | $23.18 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.68 | 2025 | Iclusig |
| Incyte Corporation | $18.62 | 2022 | |
| Sobi, INC | $17.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.